The study of the PI3K inhibitor SL-901 in patients with advanced solid tumors

The company Stemline Therapeutics, Inc is enrolling patients into the clinical trial investigating Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid Tumors.

Study STML-901-0119 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-901 in patients with Advanced Solid Tumors.

Patients will take study medication daily, with dosage based on their assigned cohort and regimen.

The trial is designed to enroll male and female 18 Years and older and is being conducted in the Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Christie Hospital, Manchester, United Kingdom.

The study start date is March 19, 2021.

This page provides a more detailed overview of this clinical trial:

Clinical Research News

Upcoming Clinical Trials